Clinical Study Evaluating the Effect of Losartan

Summary

The pancreas is two organs packaged into one. The islets of Langerhans serve critical endocrine functions, and the exocrine portion is a major source of enzymes that are essential for digestion. Pancreatic cancer (PC) is more commonly referred to as pancreatic infiltrating ductal adenocarcinoma in addition to being the second leading cause of cancer death in the United States, after lung cancer in 2020. Whereas pancreatic cancer is the seventh cause of death from cancer in Asia in 2020. Although it is substantially less common than the other malignancies, pancreatic carcinoma is near the top of the list of killers because it is a highly aggressive carry.

Eligibility

Inclusion Criteria:

* Male and female pancreatic cancer patients aged ≥ 50 years old.
* Hypertensive patient with BP ≥ 140/90 mm Hg.
* Histologically confirmed metastatic pancreatic adenocarcinoma; or locally advanced pancreatic cancer patients.
* All included patients must sign an informed consent

Exclusion Criteria:

* Patients with serious concomitant systemic disorders as significant cardiac, renal, hepatic, or pulmonary morbidity.
* Pregnant or lactating women and women of childbearing potential.
* Patients received prior systemic fluoropyrimidine therapy within the past 10 years.
* Prior un-anticipated severe reaction to fluoropyrimidine therapy, or known hypersensitivity to 5-fluorouracil, irinotecan, oxaliplatin, losartan, or any monoclonal antibody.
* Patients with an active, known, or suspected autoimmune disease such as psoriasis.
* Patients with a known positive test for hepatitis B virus surface antigen (HBV s Ag) or hepatitis C virus (HCV antibody) and patients with a known history of testing positive for (HIV) or known acquired immunodeficiency syndrome (AIDS).
* Patients received a live vaccine or live attenuated vaccines as intranasal influenza vaccines within 30 days of the planned start of study therapy.

Conditions2

Browse More Trials